The Future of Longevity Is Here and Avant Technologies (OTCQB: AVAI) is Unleashing the Power of the Klotho Protein to Turn Back the Clock on Human Aging and Age-Related Diseases.
Download The Corporate Presentation
As the global population ages faster than ever before, AVAI is harnessing the not so well known Klotho Protein for the next breakthrough in longevity medicine: designed to help this aging population live longer, healthier, and more independent lives.
Revolutionary cell therapy harnesses the Klotho protein to extend healthy lifespan, prevent age-related decline, and pioneer the next great frontier in regenerative medicine!
THE TOP REASONS TO HAVE AVAI ON YOUR RADAR:
- First-Mover in Klotho-Based Longevity Therapy: AVAI is among the only biotech firms developing a clinical-grade, cell-based delivery system for Klotho — an untapped and potentially enormous market.
- Breakthrough Technology Partnership: Collaboration with Austrianova merges world-class cell biology with proven encapsulation technology — a union designed for clinical scalability and safety.
- Scientific Validation Across Species: Research consistently demonstrates that increasing Klotho levels extends life, enhances cognition, and reduces disease risk in both animal and human studies.
- Growing Global Demand for Longevity Solutions: With populations aging rapidly, the longevity sector is expected to exceed $600 billion by 2030 — positioning AVAI in the heart of a massive megatrend.
- Sustained Therapeutic Impact with Safety Controls: The therapy’s removable nature and long-term protein release mechanism give it a superior safety profile over gene editing or permanent implants.
- Strong Leadership: CEO Chris Winter is steering Avant through a bold, high-conviction strategy focused on innovation, efficiency, and global collaboration. Winter has over thirty-five years of experience in the investment banking and commodities industries working on numerous private placements, public offerings, mergers and acquisitions. He has participated in raising over $70M throughout his career.
- Microcap Advantage: With a small market cap, Avant offers asymmetric upside potential — small valuation, big vision.
With a Bold Bet on the Future of Health, Regeneration, and Disease Prevention —AVAI is Aiming for Explosive Transformation into a Partnership-Driven Powerhouse!
A BREAKTHROUGH IN THE SCIENCE OF AGING
Avant Technologies (OTCQB: AVAI), through its 50/50 joint venture project Klothonova LLC is advancing one of the most promising longevity treatments in modern biotechnology — a removable cell therapy designed to promote a longer, healthier life.
This initiative brings together two scientific powerhouses: Avant Technologies (awaiting name change approval to AVAI Bio), a leader in next-generation cell therapies, and Austrianova, renowned for its “Cell-in-a-Box®” microencapsulation technology that acts as armor plating for living cells.
At the heart of Klothonova’s approach lies Klotho, a naturally occurring protein long recognized by researchers as a master regulator of aging.
Elevated Klotho levels are linked to longer lifespan, sharper cognition, and resistance to chronic disease — while low levels accelerate the body’s aging process.
AVAI’s goal is bold yet clear: restore youthful Klotho levels and rewrite the biological timeline of aging itself! The Klotho protein may be the key to unlocking longevity and AVAI is leading the charge!
The Klotho protein is one of the most exciting breakthroughs in the field of anti-aging and regenerative medicine. Discovered in 1997 and named after Clotho, the mythological Greek Fate who spins the thread of life, Klotho is a naturally occurring protein primarily produced in the kidneys and brain.
In simple terms, Klotho acts as a biological master regulator — a guardian molecule that influences how the body ages.
It supports critical systems including cognitive function, kidney filtration, bone health, insulin sensitivity, and cardiovascular strength. Research has shown that higher levels of Klotho are linked to longer lifespan, improved memory, better kidney and heart performance, and lower risk of degenerative diseases such as Alzheimer’s, diabetes, and cancer.
When Klotho levels decline — which happens naturally with age — the body becomes more susceptible to cellular damage, inflammation, oxidative stress, and metabolic decline.
Scientists have long believed that restoring or enhancing Klotho expression could slow, stop, or even reverse aspects of biological aging.
Avant Technologies (OTCQB: AVAI) May Have Found the Key to Longevity — The Klotho Protein Revolution Begins!
WHY IS KLOTHO A GAME-CHANGER?
- Targets the Root Cause of Aging: Instead of treating symptoms, Klotho addresses cellular and molecular mechanisms that drive aging, offering potential for broad-spectrum therapeutic benefits across multiple organs.
- Versatile Across Major Diseases: Klotho therapy has shown promise in improving outcomes in Alzheimer’s, heart disease, kidney failure, osteoporosis, and cancer — conditions that collectively represent trillions in healthcare costs each year.
- Synergistic with Modern Biotechnology: By integrating genetic engineering, stem cell science, and encapsulation technologies, Klotho-based therapies can be safely and precisely delivered to target tissues — amplifying its therapeutic power.
- Longevity Potential: In laboratory studies, restoring Klotho levels extended lifespan in animal models and improved resilience against age-related degeneration — igniting immense interest from the global scientific and investment communities.
CELL ARMOR TECHNOLOGY: PROTECTING AND EMPOWERING THERAPEUTIC CELLS
One of the major hurdles in cell therapy is immune rejection — the body attacking foreign cells before they can deliver their benefits.
Austrianova’s Cell-in-a-Box® encapsulation technology solves this problem by surrounding the Klotho-producing cells in a protective, semi-permeable shell. This “armor plating” allows nutrients and proteins to pass through freely, while keeping the immune system out.
The advantages are striking:
- Sustained, stable production of Klotho over long periods
- Minimal immune reaction or rejection risk
- Controlled, removable therapy adaptable to patient needs
In preclinical studies, encapsulated Klotho-producing cells demonstrated robust output:
- ~580 picograms of Klotho per 1,000 cells every 24 hours
- ~8,120 picograms per capsule per day
With approximately 14,000 cells per capsule, each tiny implant becomes a powerful engine of cellular rejuvenation.
TURNING KLOTHO SCIENCE INTO A REAL-WORLD THERAPY
Avant Technologies is not just talking about Klotho — it’s commercializing it through its joint venture with Austrianova.
Avant co-founded Klothonova, LLC ., a joint venture biotech company dedicated to developing and advancing Klotho-based cellular therapies using Austrianova’s proprietary cell encapsulation technology.
Here’s why this matters:
- Austrianova’s encapsulation technology protects and stabilizes living Klotho-producing cells, allowing them to survive longer and function effectively inside the body.
- This innovation solves one of the biggest hurdles in regenerative medicine — delivering therapeutic proteins safely and efficiently without immune rejection.
- Klothonova’s mission is to produce Klotho continuously inside the patient’s body, essentially turning the body into its own anti-aging system.
In the words of CEO Chris Winter,
“Klothonova represents a significant step toward addressing some of the most pressing medical challenges of our time. By partnering with Austrianova, we’re advancing transformative healthcare solutions aimed at improving patient outcomes and promoting healthier, longer lives.”
A TRILLION-DOLLAR OPPORTUNITY IN LONGEVITY SCIENCE
The longevity biotech market — valued at $27.15 billion in 2024 and expected to hit $46.61 billion by 2033 — is expanding rapidly as the world seeks answers to the challenges of aging populations.
With Klotho-based therapies, Avant Technologies and Austrianova, through Klothonova, are aiming to lead the field by developing a new class of regenerative treatments that don’t just manage disease — they rebuild health from the inside out.
This is why Klotho is often referred to as the “Holy Grail” of anti-aging research, and why Avant Technologies (OTCQB: AVAI) could emerge as one of the most compelling longevity biotech companies in the public market.
In a world where longevity is becoming the ultimate investment theme, AVAI is positioning itself as one of the few publicly traded companies at the core of a new “health span economy.”
A PARTNERSHIP MODEL THAT REDEFINES BIOTECH RISK
Instead of going it alone and burning cash in the lengthy development cycles that plague most biotech startups, AVAI is building a collaboration-first model that pairs its vision with the resources, IP, and technologies of global leaders.
By identifying the most promising genetically modified cell lines and collaborating with top-tier biotech firms, scientists, and clinicians, the company aims to share both risk and reward — dramatically accelerating product development timelines while preserving shareholder value.
CEO Chris Winter summed it up best:
“Our transition to a partnership-driven model represents a transformative step for Avant, enabling us to harness global innovations in cell therapy while mitigating traditional development challenges.”
This is not biotech business as usual — this is strategic disruption, where smart capital meets smart science.
RIDING THE $44 BILLION CELL THERAPY BOOM
Avant’s timing couldn’t be better. The global cell therapy market is in hypergrowth mode, valued at $5.88 billion in 2024 and projected to skyrocket to $44.39 billion by 2034, with a CAGR of 22.7%.
Why? Because regenerative medicine is shifting the paradigm from treating symptoms to curing disease at the cellular level. From autoimmune disorders to neurological diseases, cell-based therapies are redefining patient outcomes, offering personalized, long-term solutions that traditional pharmaceuticals simply can’t match.
The surge is fueled by:
- Rising global demand for regenerative medicine
- Increasing chronic disease prevalence
- Rapid advances in gene editing and viral vector technology
- Government funding and public-sector R&D support
And AVAI is right in the middle of it — not just as a participant, but as a strategic architect, building global alliances that deliver therapies faster and more efficiently than traditional biotech models.
WHY LONGEVITY NEEDS KLOTHONOVA NOW
As the global population ages — particularly in developed nations — healthcare systems face mounting challenges. By 2030, one in six people worldwide will be over the age of 60.
Traditional medicine focuses on treating diseases after they occur, but longevity science aims to prevent them altogether by maintaining youthful biological function.
Klotho-based therapies like Klothonova offer exactly that promise:
- Restoring metabolic balance
- Protecting against cognitive and cardiovascular decline
- Supporting renal and muscular health
- Slowing or reversing cellular aging processes
For millions of older adults — and a growing class of health-conscious individuals seeking to extend their “healthspan” rather than just lifespan — Klothonova represents a transformative shift in how we approach aging itself.
THE BOTTOM LINE
Avant Technologies (OTCQB: AVAI) is not just chasing biotech trends — it’s engineering the future of health. Through its ecosystem of global partnerships, the company is connecting cell therapy into one coherent mission: to extend life, restore function, and redefine what “aging” means.
In an investment landscape hungry for true innovation, AVAI stands out as a company with tangible progress, real partnerships, and a vision bold enough to lead.
The market is extensive…. The global population is aging faster than at any point in history — and it’s triggering one of the biggest healthcare and economic transformations of our time.
Klothonova isn’t just a therapy — it’s a blueprint for reengineering the biology of aging. By restoring youthful levels of the Klotho protein, Avant Technologies may hold the key to unlocking longer, stronger, and healthier lives.
In a world racing toward longevity innovation, AVAI stands at the threshold of a medical revolution — one where age may finally become a condition we can treat, manage, and perhaps even reverse!
Discover how AVAI is turning the groundbreaking science of the Klotho protein into real-world longevity solutions — and why this could be one of the most thrilling health tech breakthroughs of the decade! Start your research!
Learn More about Avant Technologies. by gaining access to the latest corporate presentation
Download PRESENTATIONTHIS IS A PAID ADVERTISEMENT
NO INVESTMENT ADVICE
Copyright 2025 © SCDalerts.com is owned and operated by the owner of SCD Media LLC.
Disclaimer and Privacy For more Information please contact info@smallcapsdaily.co
This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.
SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses.
You received this message as part of your subscription to SCD Alerts.
SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above.
If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only.
Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here.
We do not own any shares in AVAI. We have been currently compensated up to Twenty Five Hundred Dollars Cash ($2,500) via bank wire transfer from a third-party Interactive Offers, LLC for landing page hosting for AVAI with a start date of 10/09/2025. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.
Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct.
Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications.
The information in our disclaimers is subject to change at any time without notice.